Lupin gets USFDA nod for marketing testosterone topical solution
Testosterone topical solution are indicated for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone
 "Lupin gets USFDA nod for marketing testosterone topical solution")
Drug firm Lupin on Wednesday said it has received the final approval from the US health regulator for its testosterone topical solution.
The company has received final approval for its testosterone topical solution, 30 mg per actuation from the United States Food and Drug Administration (USFDA) to market the product, Lupin said in a BSE filing.
The approved product is a generic version of Eli Lilly and Company's Axiron topical solution, it added.
According to IMS MAT June 2017 data, testosterone topical solution had sales of $244.2 million in the US, Lupin said.
The testosterone topical solution are indicated for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone, it added.
Shares of Lupin were trading at Rs 1028.50, up 0.19 per cent from the previous close on BSE.